A Phase 1, Open-label, Study of Voruciclib in Subjects With Relapsed and/or Refractory B Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary) ; Voruciclib (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions
- Sponsors MEI Pharma
- 13 Nov 2019 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.
- 13 Nov 2019 Planned primary completion date changed from 31 Jul 2019 to 30 Apr 2022.
- 05 Mar 2019 Planned number of patients changed from 63 to 84.